The specter of generic challenges has consistently loomed around copyright’s iconic drug, Viagra, sparking questions about the future of related drug holdings. While early periods saw impressive profits, the patent expiration has allowed the path for cheaper alternatives, potentially diminishing profitability and creating a real risk for stakehol